ENTA News and Press, Enanta Pharmaceuticals Inc. From 08/07/23

Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. Cash and Marketable Securities Totaled $392.5 ...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on Au...

2023-06-23 16:14:00 ET Summary Enanta Pharmaceuticals faces challenges due to lack of profitability and sales growth, as well as unwise R&D investments. The company's royalty structures are attractive but do not mitigate downside factors, leading to a neutral investment view. ...

- Generally Safe and Well-Tolerated up to 800 mg for Seven Days with Pharmacokinetics Supportive of Once-Daily Dosing - All Doses Resulted in Strong Exposure Multiples Against Both RSV A and B Strains - Human Challenge Study to be Initiated by Early Fourth Quarter 2023 ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Associ...

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare...

2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...

2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...

2023-05-10 14:51:24 ET Enanta Pharma press release ( NASDAQ: ENTA ): Q2 GAAP EPS of -$1.79 beats by $0.45 . Revenue of $17.8M (-4.9% Y/Y) beats by $4.91M . For further details see: Enanta Pharma GAAP EPS of -$1.79 beats by $0.45, revenue of $17.8M beats b...

2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...